Co-Diagnostics
CODX
43 hedge funds and large institutions have $4.83M invested in Co-Diagnostics in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 5 closing their positions.
266% more call options, than puts
Call options by funds: $172K | Put options by funds: $47K
0% more funds holding
Funds holding: 43 → 43 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.1% less ownership
Funds ownership: 14.67% → 14.57% (-0.1%)
2% less capital invested
Capital invested by funds: $4.93M → $4.83M (-$94.9K)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$84.4K |
| 2 |
KOC
Koss-Olinger Consulting
Gainesville,
Florida
|
+$58.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$56.6K |
| 4 |
Jane Street
New York
|
+$32.5K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$30.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$93.3K |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$90.1K |
| 3 |
Renaissance Technologies
New York
|
-$21.8K |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$12.6K |
| 5 |
Morgan Stanley
New York
|
-$10.1K |
CODX Hedge Fund Activity: Q3 2023 in Review
43 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q3 2023, worth a combined $4.83M — down 1.9% from $4.93M a quarter earlier.
Fund positioning in CODX was balanced in Q3 2023: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 11 trimmed.
The largest buyer was Kestra Advisory Services, adding an estimated $84.4K. The largest seller was Man Group, exiting entirely with an estimated $93.3K sold.
- 43 institutional investors held Co-Diagnostics (CODX) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $4.83M of Co-Diagnostics stock for Q3 2023, down 1.9% quarter-over-quarter.
- 5 funds opened new Co-Diagnostics positions in Q3 2023 and 5 closed out, a net change of 0 holders.
- The largest Co-Diagnostics buyer in Q3 2023 was Kestra Advisory Services, an estimated $84.4K added.
- The largest Co-Diagnostics seller in Q3 2023 was Man Group, an estimated $93.3K sold.
Based on aggregated 13F filings for Q3 2023.